Stay ahead with the most recent pipeline outlook for Acromegaly. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Acromegaly Treatment Drugs The ...

The FDA rounded out the month with the approval of remibrutinib (Rhapside; Novartis), a highly selective Bruton tyrosine kinase inhibitor (BTKi), for patients with chronic spontaneous urticaria (CSU) ...

Investing.com - Piper Sandler maintained its Overweight rating and $97.00 price target on Crinetics Pharmaceuticals (NASDAQ:CRNX) following the recent approval of its acromegaly treatment PALSONIFY.

Leerink believes current consensus numbers for Crinetics appear achievable based on their analysis of Palsonify’s market potential in acromegaly treatment. In other recent news, Crinetics ...

PITTSBURGH, Oct. 13, 2025 /PRNewswire/ — PANTHERx ® Rare has been chosen by Chiesi as the exclusive specialty pharmacy to ...

Investing.com - Piper Sandler has reiterated an Overweight rating and $97.00 price target on Crinetics (NASDAQ:CRNX) following FDA approval of its acromegaly treatment PALSONIFY. The stock has surged ...

Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under ...

We recently published 10 Big Names With Explosive Gains That Investors Can’t Ignore. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the companies that soared by double- and triple-digits last ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on October 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...

The gastrointestinal neuroendocrine tumors market is experiencing steady growth driven by increasing disease prevalence, improved diagnostic capabilities, and rising awareness of targeted therapies.

Pharmaceuticals announced three abstracts from its clinical development programs will be presented at the upcoming North American ...